{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:47:34Z","timestamp":1794052054870,"version":"4.8.0"},"reference-count":154,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with a poor prognosis, associated with asbestos exposure. Nowadays, treatment is based on chemotherapy with a median overall survival of less than two years. This review highlights the main characteristics of the immune microenvironment in MPM with special emphasis on recent biological advances. The MPM microenvironment is highly infiltrated by tumour-associated macrophages, mainly M2-macrophages. In line with infiltration by M2-macrophages, which contribute to immune suppression, other effectors of innate immune response are deficient in MPM, such as dendritic cells or natural killer cells. On the other hand, tumour infiltrating lymphocytes (TILs) are also found in MPM, but CD4+ and CD8+ TILs might have decreased cytotoxic effects through T-regulators and high expression of immune checkpoints. Taken together, the immune microenvironment is particularly heterogeneous and can be considered as mainly immunotolerant or immunosuppressive. Therefore, identifying molecular vulnerabilities is particularly relevant to the improvement of patient outcomes and the assessment of promising treatment approaches.<\/jats:p>","DOI":"10.3390\/cancers13133205","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T22:24:57Z","timestamp":1624832697000},"page":"3205","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Anne-Laure","family":"D\u00e9sage","sequence":"first","affiliation":[{"name":"Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-935X","authenticated-orcid":false,"given":"Georgia","family":"Karpathiou","sequence":"additional","affiliation":[{"name":"Pathology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5453-0021","authenticated-orcid":false,"given":"Michel","family":"Peoc\u2019h","sequence":"additional","affiliation":[{"name":"Pathology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios E.","family":"Froudarakis","sequence":"additional","affiliation":[{"name":"Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/oem.17.4.260","article-title":"Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Occup. Environ. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/bmj.1.5431.350","article-title":"Diffuse Mesothelioma of the Pleura and Asbestos","volume":"1","author":"Elmes","year":"1965","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(07)60412-7","article-title":"Ecological association between asbestos-related diseases and historical asbestos consumption: An international analysis","volume":"369","author":"Lin","year":"2007","journal-title":"Lancet"},{"key":"ref_4","first-page":"491","article-title":"Malignant pleural mesothelioma: An epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003\u20132008","volume":"19","author":"Henley","year":"2013","journal-title":"Int. J. Occup. Environ. Heal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","article-title":"The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification","volume":"11","author":"Churg","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-017-2109-z","article-title":"Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies","volume":"470","author":"Habougit","year":"2017","journal-title":"Virchows Archiv"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in Malignant Mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"New Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.rmed.2015.05.014","article-title":"Pleural neoplastic pathology","volume":"109","author":"Karpathiou","year":"2015","journal-title":"Respir. Med."},{"key":"ref_15","first-page":"792","article-title":"Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells","volume":"55","author":"Ault","year":"1995","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"L471","DOI":"10.1152\/ajplung.1995.268.3.L471","article-title":"Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: Role of iron-catalyzed free radicals","volume":"268","author":"Kamp","year":"1995","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_17","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3892\/ijo.2017.3991","article-title":"Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure","volume":"50","author":"Maeda","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3892\/ijo.2016.3776","article-title":"Accelerated cell cycle progression of human regulatory T cell-like cell line caused by continuous exposure to asbestos fibers","volume":"50","author":"Lee","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/djs513","article-title":"Pleural plaques and the risk of pleural mesothelioma","volume":"105","author":"Pairon","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_24","first-page":"955","article-title":"Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region","volume":"9","author":"Sainio","year":"2002","journal-title":"Oncol. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","article-title":"Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours","volume":"22","author":"Renier","year":"2003","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_30","first-page":"1","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant Pleural Mesothelioma: From the Bench to the Bedside","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Minnema-Luiting, J., Vroman, H., Aerts, J., and Cornelissen, R. (2018). Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041041"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cornelissen, R., Lievense, L.A., Maat, A.P., Hendriks, R.W., Hoogsteden, H.C., Bogers, A.J., Hegmans, J.P., and Aerts, J.G. (2014). Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106742"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of Dendritic Cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1082028","DOI":"10.1080\/2162402X.2015.1082028","article-title":"Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes","volume":"5","author":"Cornwall","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Tolani, B., Acevedo, L.A., Hoang, N.T., and He, B. (2018). Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010238"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate\u2013pulsed Dendritic Cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"ref_46","first-page":"1","article-title":"Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients","volume":"2015","author":"Nishimura","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.imlet.2016.05.007","article-title":"Human NK cells: From surface receptors to clinical applications","volume":"178","author":"Moretta","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1177\/039463200902200304","article-title":"Impairment in Cytotoxicity and Expression of NK Cell- Activating Receptors on Human NK Cells following Exposure to Asbestos Fibers","volume":"22","author":"Nishimura","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or Adaptive Immunity? The Example of Natural Killer Cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-014-1597-9","article-title":"Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma","volume":"63","author":"Wu","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.2910520609","article-title":"Establishment of a murine model of malignant mesothelioma","volume":"52","author":"Davis","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: A multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/ijc.32363","article-title":"NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy","volume":"145","author":"Sottile","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate Lymphoid Cells: 10 Years On","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2014A proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.32262","article-title":"Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor","volume":"145","author":"Tumino","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","article-title":"Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non\u2013Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv. Anat. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: Immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"55828","DOI":"10.18632\/oncotarget.10094","article-title":"Positive and negative functions of B lymphocytes in tumors","volume":"7","author":"Shen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3109\/08923973.2014.890626","article-title":"Anti-CD40-mediated cancer immunotherapy: An update of recent and ongoing clinical trials","volume":"36","author":"Hassan","year":"2014","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbrc.2015.02.158","article-title":"Optimization of anti-CD20 humanized antibody hu8E4 by site-directed mutation based on epitope analysis","volume":"459","author":"Chen","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.imlet.2014.01.011","article-title":"The selection of mature B cells is critically dependent on the expression level of the co-receptor CD19","volume":"160","author":"Engdahl","year":"2014","journal-title":"Immunol. Lett."},{"key":"ref_67","first-page":"1","article-title":"The Roles of CD73 in Cancer","volume":"2014","author":"Gao","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_68","first-page":"74","article-title":"Tumor immune microenvironment characterization and response to anti-PD-1 therapy","volume":"12","author":"Santarpia","year":"2015","journal-title":"Cancer Biol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.intimp.2015.04.037","article-title":"Trastuzumab-based chemotherapy modulates systemic redox homeostasis in women with HER2-positive breast cancer","volume":"27","author":"Lemos","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.4049\/jimmunol.1402236","article-title":"B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis","volume":"194","author":"Harp","year":"2015","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","article-title":"Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells","volume":"176","author":"Crawford","year":"2006","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/eji.1830260332","article-title":"Activated B cells express functional Fas ligand","volume":"26","author":"Hahne","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"ref_74","first-page":"11915","article-title":"Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1172\/JCI59266","article-title":"Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice","volume":"121","author":"Horikawa","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-014-0304-0","article-title":"Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer","volume":"12","author":"Zhou","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.canlet.2014.09.026","article-title":"Regulatory B cells accelerate hepatocellular carcinoma progression via CD40\/CD154 signaling pathway","volume":"355","author":"Shao","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.4049\/jimmunol.1402568","article-title":"CD4+T Cell\u2013Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B\u2013Expressing Regulatory B Cells in HIV Patients","volume":"194","author":"Kaltenmeier","year":"2015","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: Correlation with clinical\u2013pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_81","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"South. Afr. Med. J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_83","first-page":"1157","article-title":"Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A Feasibility Study Evaluating Surgery for Mesothelioma after Radiation Therapy: The \u201cSMART\u201d Approach for Resectable Malignant Pleural Mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4049\/jimmunol.2000487","article-title":"Foxp3+ Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma","volume":"205","author":"Kohno","year":"2020","journal-title":"J. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e1278330","DOI":"10.1080\/2162402X.2016.1278330","article-title":"Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma","volume":"6","author":"Kiyotani","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2016.04.015","article-title":"Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients","volume":"107","author":"Lievense","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2019.02.005","article-title":"High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes","volume":"130","author":"Ahmadzada","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: A meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_92","first-page":"516","article-title":"Inflammation in malignant mesothelioma-friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann. Cardiothorac. Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000356764","article-title":"Prognostic Factors in Patients Presenting with Pleural Effusion Revealing Malignancy","volume":"87","author":"Anevlavis","year":"2014","journal-title":"Respiration"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-10-2245","article-title":"High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy","volume":"16","author":"Kao","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/JTO.0b013e31822a3740","article-title":"Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy","volume":"6","author":"Kao","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_96","first-page":"1898","article-title":"Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy","volume":"7","author":"Tagawa","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2147\/TCRM.S104077","article-title":"Are neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?","volume":"12","author":"Onur","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2015.07.014","article-title":"Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma","volume":"90","author":"Yamagishi","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Duruisseaux","year":"2016","journal-title":"Hum. Pathol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Cedr\u00e9s, S., Ponce-Aix, S., Zugazagoitia, J., Sansano, I., Enguita, A., Navarro-Mendivil, A., Martinez-Marti, A., Martinez, P., and Felip, E. (2015). Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121071"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.pathol.2020.09.018","article-title":"Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status","volume":"53","author":"Rrapaj","year":"2021","journal-title":"Pathology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T Cells in PD-L1\u2013Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/cncy.22401","article-title":"Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma","volume":"129","author":"Mansour","year":"2021","journal-title":"Cancer Cytopathol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"ref_108","first-page":"269","article-title":"LAG-3 in Cancer Immunotherapy","volume":"344","author":"Goldberg","year":"2010","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 Immune Checkpoint Protein in Human Cancer","volume":"27","author":"Fodstad","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/pin.13028","article-title":"Expression status of PD-L1 and B7-H3 in mesothelioma","volume":"70","author":"Matsumura","year":"2020","journal-title":"Pathol. Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4049\/jimmunol.177.2.1052","article-title":"CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism","volume":"177","author":"Engelhardt","year":"2006","journal-title":"J. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.4049\/jimmunol.181.3.1683","article-title":"Acquisition of suppressive function by activated human CD4+ CD25- T cells is associated with the expression of CTLA-4 not FoxP3","volume":"181","author":"Zheng","year":"2008","journal-title":"J. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","article-title":"CTLA-4 in mesothelioma patients: Tissue expression, body fluid levels and possible relevance as a prognostic factor","volume":"65","author":"Roncella","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/imr.12525","article-title":"Immunoregulatory functions of VISTA","volume":"276","author":"Nowak","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/modpathol.2017.89","article-title":"Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients","volume":"30","author":"Kakavand","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","article-title":"Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions","volume":"48","author":"Alcala","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant Mesothelioma Effusions Are Infiltrated by CD3 + T Cells Highly Expressing PD-L1 and the PD-L1 + Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti\u2013PD-L1 Antibody Avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/j.jtho.2020.08.004","article-title":"ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743","volume":"15","author":"Baas","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Marcq, E., Van Audenaerde, J.R.M., De Waele, J., Jacobs, J., Van Loenhout, J., Cavents, G., Pauwels, P., van Meerbeeck, J.P., and Smits, E.L.J. (2019). Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174182"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in Malignant Pleural Mesothelioma","volume":"10","author":"Borm","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0631-0","article-title":"Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma","volume":"11","author":"Ladanyi","year":"2019","journal-title":"Genome Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"798467","DOI":"10.1155\/2010\/798467","article-title":"Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity","volume":"2010","author":"Veltman","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human","volume":"24","author":"Aerts","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00264-1","article-title":"Anti-Mesothelin CAR T cell therapy for malignant mesothelioma","volume":"9","author":"Castelletti","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Burgio, S., Noori, L., Gammazza, A.M., Campanella, C., Logozzi, M., Fais, S., Bucchieri, F., Cappello, F., and Bavisotto, C.C. (2020). Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155432"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Kara-Terki, L., Treps, L., Blanquart, C., and Fradin, D. (2020). Critical Roles of Tumor Extracellular Vesicles in the Microenvironment of Thoracic Cancers. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176024"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"102949","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bcmd.2005.03.003","article-title":"Exosomes and the MICA-NKG2D system in cancer","volume":"34","author":"Clayton","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4049\/jimmunol.1003884","article-title":"Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production","volume":"187","author":"Clayton","year":"2011","journal-title":"J. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-019-0980-8","article-title":"Extracellular vesicles in the tumor microenvironment: Old stories, but new tales","volume":"18","author":"Han","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"22492","DOI":"10.3402\/jev.v2i0.22492","article-title":"Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma","volume":"2","author":"Mahaweni","year":"2013","journal-title":"J. Extracell. Vesicles"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-018-0423-x","article-title":"33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018), Washington, D.C., USA, 7\u201311 November 2018","volume":"6","author":"Berry","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omtn.2018.11.003","article-title":"An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS\/STING Pathway in Pan-Cancer","volume":"14","author":"An","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"113113","DOI":"10.1016\/j.ejmech.2020.113113","article-title":"STING, a promising target for small molecular immune modulator: A review","volume":"211","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3205\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:57Z","timestamp":1760163897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/13\/3205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":154,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13133205"],"URL":"https:\/\/doi.org\/10.3390\/cancers13133205","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]}}}